Literature DB >> 6237711

Spectinomycin as initial treatment for gonorrhoea.

C S Easmon, G E Forster, G D Walker, C A Ison, J R Harris, P E Munday.   

Abstract

The prevalence of penicillinase producing Neisseria gonorrhoeae at this hospital increased exponentially from less than 0.5% in 1978 to 6.5% of all isolates in 1982. In January 1983 first line treatment for uncomplicated heterosexual anogenital gonorrhoea was therefore changed from ampicillin and probenecid to spectinomycin. This subsequently cured 95% of cases seen at the Praed Street Clinic. Although there was an initial fall in the monthly isolation rate of penicillinase producing N gonorrhoeae after the introduction of spectinomycin, this was not maintained. The exponential increase in the prevalence of the strain did slow in 1983, rising to only 8.7%. This, however, may have reflected a general decline in the rate of increase of penicillinase producing N gonorrhoeae throughout Britain. The failure to influence the prevalence of penicillinase producing N gonorrhoeae to any great degree may have been due in part to spectinomycin resistance in both penicillinase producing and non-penicillinase-producing N gonorrhoeae. All of the isolates appeared identical, apart from the presence of the 4.4 megadalton plasmid in penicillinase producing N gonorrhoeae, but they could not be linked epidemiologically. Changing treatment in only one of the many venereal diseases clinics in London, where patients have open access to all such clinics, is unlikely to affect the prevalence of penicillinase producing N gonorrhoeae. This has probably been more important than spectinomycin resistance in limiting the effectiveness of spectinomycin in reducing the prevalence of the strain.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6237711      PMCID: PMC1443055          DOI: 10.1136/bmj.289.6451.1032

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  8 in total

1.  A rapid alkaline extraction procedure for screening recombinant plasmid DNA.

Authors:  H C Birnboim; J Doly
Journal:  Nucleic Acids Res       Date:  1979-11-24       Impact factor: 16.971

2.  Nutritional profiles of Neisseria gonorrhoeae, Neisseria meningitidis, and Neisseria lactamica in chemically defined media and the use of growth requirements for gonococcal typing.

Authors:  B W Catlin
Journal:  J Infect Dis       Date:  1973-08       Impact factor: 5.226

3.  Penicillinase-producing Neisseria gonorrhoeae--a retrospective.

Authors:  W M McCormack
Journal:  N Engl J Med       Date:  1982-08-12       Impact factor: 91.245

4.  Penicillinase-producing Gonococci in Liverpool.

Authors:  A Percival; J Rowlands; J E Corkill; C D Alergant; O P Arya; E Rees; E H Annels
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

5.  Penicillinase-producing Neisseria gonorrhoeae in Great Britain, 1977-81: alarming increase in incidence and recent development of endemic transmission.

Authors:  J A McCutchan; M W Adler; J R Berrie
Journal:  Br Med J (Clin Res Ed)       Date:  1982-07-31

6.  Epidemiology of PPNG infections in Amsterdam: analysis by auxanographic typing and plasmid characterisation.

Authors:  M C Ansink-Schipper; M H Huikeshoven; R K Woudstra; B van Klingeren; G A de Koning; D Tio; F J Schoonhoven; R A Coutinho
Journal:  Br J Vener Dis       Date:  1984-02

7.  Gonococcal W serogroups in Scandinavia. A study with polyclonal and monoclonal antibodies.

Authors:  S Bygdeman; D Danielsson; E Sandström
Journal:  Acta Pathol Microbiol Immunol Scand B       Date:  1983-10

8.  Imported penicillinase producing Neisseria gonorrhoeae becomes endemic in London.

Authors:  R N Thin; D Barlow; S Eykyn; I Phillips
Journal:  Br J Vener Dis       Date:  1983-12
  8 in total
  13 in total

Review 1.  Antimicrobial agents and gonorrhoea: therapeutic choice, resistance and susceptibility testing.

Authors:  C A Ison
Journal:  Genitourin Med       Date:  1996-08

Review 2.  Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future.

Authors:  Magnus Unemo; William M Shafer
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

3.  Penicillinase producing gonococci: a spent force?

Authors:  C A Ison; J Gedney; J R Harris; C S Easmon
Journal:  Genitourin Med       Date:  1986-10

Review 4.  Neisseria gonorrhoeae: a versatile pathogen.

Authors:  C S Easmon; C A Ison
Journal:  J Clin Pathol       Date:  1987-09       Impact factor: 3.411

Review 5.  Molecular approaches to enhance surveillance of gonococcal antimicrobial resistance.

Authors:  Namraj Goire; Monica M Lahra; Marcus Chen; Basil Donovan; Christopher K Fairley; Rebecca Guy; John Kaldor; David Regan; James Ward; Michael D Nissen; Theo P Sloots; David M Whiley
Journal:  Nat Rev Microbiol       Date:  2014-02-10       Impact factor: 60.633

6.  Testing sensitivity of Neisseria gonorrhoeae to spectinomycin.

Authors:  J M Hilton; C A Ison; C S Easmon
Journal:  Genitourin Med       Date:  1985-08

7.  Antimicrobial susceptibility testing of Neisseria gonorrhoeae: a trial organised as part of the United Kingdom national external quality assessment scheme for microbiology.

Authors:  J J Snell; D F Brown
Journal:  J Clin Pathol       Date:  1988-01       Impact factor: 3.411

8.  Chromosomal resistance of gonococci to antibiotics.

Authors:  C A Ison; J Gedney; C S Easmon
Journal:  Genitourin Med       Date:  1987-08

9.  Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline.

Authors:  R N Jones; T L Gavan; C Thornsberry; P C Fuchs; E H Gerlach; J S Knapp; P Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

Review 10.  Antimicrobial Resistance Expressed by Neisseria gonorrhoeae: A Major Global Public Health Problem in the 21st Century.

Authors:  Magnus Unemo; Carlos Del Rio; William M Shafer
Journal:  Microbiol Spectr       Date:  2016-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.